What changed in this filing

/stocks — the workspaceLOADING

Item 5. Market for Registrant’s Common Equity

2025-04-15 compared with 2024-03-22 · 21 added, 31 removed, 35 unchanged (60% of the section changed)

2 unchanged sentences

Market Information

Our common stock is currently quoted on the OTCPink

tier of the over-the counter market maintained by OTC Markets Group, Inc.

Our common stock is currently quoted on the

OTC Pink tier of the over-the-counter market maintained by OTC Markets Group, Inc.

under the symbol “ SSII.

” However, the trading

market for our common stock is sporadic and extremely limited.

Moreover, until the review of the Form 15c2-11 which has been filed with

FINRA on our behalf is completed and cleared (as to which no assurance can be given), our common stock is not eligible for proprietary

broker-dealer quotations and may only be bought or sold in unsolicited customer orders.

This further limits the trading market for our

common stock.

However, the trading market for our common stock is sporadic and extremely limited.

Moreover, until the review of the Form 15c2-11

which has been filed with FINRA on our behalf is cleared by FINRA (as to which no assurance can be given), our common stock is not

eligible for proprietary broker-dealer quotations on the over-the-counter market and may only be bought or sold in unsolicited

customer orders.

This further limits the trading market for our common stock.

The Company has also applied to list its common stock

on the Nasdaq Stock Market, LLC, although there is no assurance that such application will be approved or that in either case, a

liquid trading market for the common stock will develop and be sustained.

Holders of our Common Stock

16 unchanged sentences

options, grants

price of outstanding

options, grants

available for future

4 unchanged sentences

Equity compensation plans not approved by security holders

12,181,226 (1)

4,891,213 (1)

Represents shares of common stock under our 2016 Incentive Stock Plan (the “ Incentive Plan ”).

As of the date of this Annual Report, 12,181,226 shares of common stock (comprised of 7,880,059 stock options and 4,301,167 stock grants) were issued under the Incentive Stock Plan.

As of the date of this Annual Report, an additional 4,891,213 shares of common stock are available for future issuances under the Incentive Stock Plan.

(1) Represents

shares of common stock under our 2016 Incentive Stock Plan (the “ Incentive Plan ”).

As of the date of this Annual Report,

12,142,838 shares of common stock (comprised of 7,767,431 stock options and 4,375,407 stock grants) were issued under the Incentive Stock

As of the date of this Annual Report, an additional 7,213,096 shares of common stock are available for future issuances under the

Incentive Stock Plan.

Recent Sales of Unregistered Securities

In October 2023, the Company issued 90,514 shares

of our common stock upon the exercise of warrants previously sold to two accredited investors at an exercise price of $4.00 per share

generating $362,056 in total proceeds.

In October 2023, the Company issued 3,000 shares

of common stock to a consultant in exchange for advisory services to be rendered over a 12-month period effective June 2023.

In October 2023, the Company issued 50,000 shares

In March 2024, the Company issued 15,000 shares

of common stock to an investor relations firm for investor relations and digital marketing services.

In November 2023, the Company issued 116,348 shares

of common stock to Dr.

Somashekhar, a director, in exchange for advisory services to be rendered over a five-year period.

In November 2023, the Company issued a total of

22,541 shares of common stock to five physician consultants, in exchange for advisory services to be rendered over a five-year period.

In November 2023, the Company issued 75,000 shares

of common stock to a firm that conducted online investment seminars in which the Company participated.

In August 2024, the Company issued 125,000 shares

to certain doctors/proctors for providing their proctoring/mentoring services.

In December 2024, the Company issued 9,034 shares

of common stock upon the exercise of warrants previously sold to three accredited investors at an exercise price of $4.00 per share, generating

$50,000 in total proceeds.

of common stock to a marketing advisory services firm for providing dedicated support, production, graphics, post-production and distribution

All of the foregoing securities were

3 unchanged sentences

Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.

What changed 10-K

Item 5. Market for Registrant’s Common Equity